PepGen Inc Sustainability Reports
PepGen Inc. is a clinical-stage biotechnology company developing peptide-conjugated oligonucleotide therapeutics. The company focuses on treating severe genetic neuromuscular and neurological diseases, such as myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG012232627
1 reports from 2023 to 2023
Company Profile
PepGen Inc. is a clinical-stage biotechnology company developing peptide-conjugated oligonucleotide therapeutics. The company focuses on treating severe genetic neuromuscular and neurological diseases, such as myotonic dystrophy type 1 and Duchenne muscular dystrophy.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
